3 Drugs Stocks Dragging The Industry Down

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 17 points (0.1%) at 16,651 as of Thursday, May 29, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,820 issues advancing vs. 1,121 declining with 182 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Allergan ( AGN), up 1.4%, Bristol-Myers Squibb Company ( BMY), up 1.3%, GlaxoSmithKline ( GSK), up 1.0% and Valeant Pharmaceuticals International ( VRX), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Pharmacyclics ( PCYC) is one of the companies pushing the Drugs industry lower today. As of noon trading, Pharmacyclics is down $2.46 (-2.8%) to $85.94 on average volume. Thus far, 639,935 shares of Pharmacyclics exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $85.85-$89.00 after having opened the day at $88.54 as compared to the previous trading day's close of $88.40.

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. Pharmacyclics has a market cap of $6.6 billion and is part of the health care sector. Shares are down 16.4% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Pharmacyclics a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Pharmacyclics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including poor profit margins and feeble growth in the company's earnings per share. Get the full Pharmacyclics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Endo International ( ENDP) is down $1.99 (-2.7%) to $71.57 on light volume. Thus far, 1.1 million shares of Endo International exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $71.45-$73.90 after having opened the day at $73.56 as compared to the previous trading day's close of $73.56.

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. Endo International has a market cap of $11.2 billion and is part of the health care sector. Shares are up 9.0% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Endo International a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Endo International as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and weak operating cash flow. Get the full Endo International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.38 (-0.8%) to $50.54 on light volume. Thus far, 1.5 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.2 million shares. The stock has ranged in price between $50.26-$50.91 after having opened the day at $50.60 as compared to the previous trading day's close of $50.92.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $44.2 billion and is part of the health care sector. Shares are up 27.1% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists